Vimian Group AB reported first-quarter revenue of 116 million euros, representing an 8% increase compared with the same period a year earlier. The company said organic growth was 9%, exceeding consensus estimates by 2 percentage points.
Adjusted EBITA for the quarter came in at 29.2 million euros, up 3% year-over-year and beating analyst expectations by 4%. The company recorded an EBITA margin of 25.2% for the period, down from 26.3% in the first quarter of 2025.
Segment performance
Diagnostics led the pack with revenue of 7.1 million euros, reflecting reported growth of 19% and organic growth of 12%. Veterinary Services posted 17.5 million euros in revenue, up 13% on a reported basis and 11% organically.
Specialty Pharma remained the largest contributor with revenue of 47.6 million euros and delivered 10% organic growth. MedTech generated 43.9 million euros in revenue with 6% organic growth; the company noted sequential improvement in MedTech supported by dental operations and recovering orthopedics markets outside the United States.
Margins and drivers
Specialty Pharma’s adjusted EBITA margin expanded to 30.3% from 28.8% a year earlier, a change the company attributed to operating leverage. By contrast, MedTech’s margin contracted to 27.1% from 29.4%, reflecting continued investments in orthopedics growth initiatives.
Veterinary Services experienced a margin decline to 27.5% from 30.3%, as the company invested in entering new markets. Diagnostics margin eased slightly to 13.8% from 14.2%, which the company attributed to an unfavorable product mix.
Overall, the quarter combined revenue growth with selective margin pressure where Vimian is directing resources toward expansion and growth programs. The results show a mix of margin improvement in certain segments alongside targeted investment-driven declines in others.
What this means for markets
- Revenue and adjusted EBITA outperformance may attract attention from investors tracking veterinary care and healthcare services names.
- Segment-level margin movements highlight where the company is deploying capital - namely orthopedics and new market entry initiatives.
- Diagnostics and Specialty Pharma are notable contributors to growth in the quarter.